About Interferon gamma receptor 2
Interferon gamma receptor 2 (IFNGR2) is a protein
from Homo sapiens identified by UniProt accession
P38484, 337 residues long.
MolForge cross-references it against 0 known binders and
259 disease associations.
Target properties
| Protein name | Interferon gamma receptor 2 |
|---|
| UniProt accession | P38484 |
|---|
| Gene | IFNGR2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 337 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (259)
Diseases linked to this target (Open Targets).
- immunodeficiency 28 · score 0.74
- Mendelian susceptibility to mycobacterial diseases due to complete IFNgammaR2 deficiency · score 0.69
- chronic granulomatous disease · score 0.47
- osteopetrosis · score 0.44
- neoplasm · score 0.41
- Friedreich ataxia · score 0.36
- Crohn's disease · score 0.35
- idiopathic pulmonary fibrosis · score 0.34
- rheumatoid arthritis · score 0.31
- neurodegenerative disease · score 0.31
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P38484-F1 | alphafold | PREDICTED | 83.76 | — |
Amino-acid sequence (337 residues)
MRPTLLWSLL LLLGVFAAAA AAPPDPLSQL PAPQHPKIRL YNAEQVLSWE PVALSNSTRP VVYQVQFKYT DSKWFTADIM SIGVNCTQIT ATECDFTAAS PSAGFPMDFN VTLRLRAELG ALHSAWVTMP WFQHYRNVTV GPPENIEVTP GEGSLIIRFS SPFDIADTST AFFCYYVHYW EKGGIQQVKG PFRSNSISLD NLKPSRVYCL QVQAQLLWNK SNIFRVGHLS NISCYETMAD ASTELQQVIL ISVGTFSLLS VLAGACFFLV LKYRGLIKYW FHTPPSIPLQ IEEYLKDPTQ PILEALDKDS SPKDDVWDSV SIISFPEKEQ EDVLQTL
Explore Interferon gamma receptor 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets